Hemophilia B Market Insights report from DelveInsight provides a thorough understanding of the Hemophilia B Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Hemophilia B Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.
Hemophilia B Overview
Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia type is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. The two main symptoms are bleeding for longer than normal, and bruising easily. With this disease, even a small bump to the head can be serious. Hemophilia B can range from mild to moderate to severe. Individuals with mild hemophilia have factor IX levels between 5 and 40% of normal; those with moderate hemophilia have factor levels from 1 to 5% of normal; and individuals with severe hemophilia have factor levels <1% of normal.
Download Sample Report- https://www.delveinsight.com/sample-request/hemophilia-b-market
Regions covered in the report
Key highlights of the Hemophilia B Market
Hemophilia B Epidemiology Insights
The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia B epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia B, Severity-specific Prevalent Pool of Hemophilia B, Prevalent population of Hemophilia B with or without Inhibitors and Treated Prevalent Population of Hemophilia B] scenario of Hemophilia B in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.
Hemophilia B Treatment Market
Currently, there is no cure for hemophilia B; however, the condition can be managed with the help of available treatment choices. In order to achieve sufficient blood clotting and avoid complications associated with the condition, the basic treatment of hemophilia B is the replacement of factor IX. At present, recombinant products or products extracted from human blood or plasma are widely used to substitute factor IX to achieve an adequate amount. Apart from this, Fresh frozen plasma is also used for treatment purposes. It is extracted from human blood and is used only when factor IX concentrate is not available to treat patients with factor IX deficiency. Currently, recombinant factor IX concentrates such as Alprolix, Benefix, Idelvion, Ixinity, Rebinyn, and Rixubis are licensed in the United States for the treatment of hemophilia B. Apart from these, bypassing agents such as Feiba, Novoseven, and Sevenfact and human plasma-derived coagulation factor IX – AlphaNine SD and Mononine – have bagged the FDA approval as well.
Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/hemophilia-b-market
Hemophilia B Marketed Drugs
Hemophilia B Emerging Drugs
Hemophilia B Pipeline Development Activities
The drugs which are in pipeline include:
1. Etranacogene dezaparvovec (AMT-061): UniQure Biopharma B.V./ CSL Behring
2. Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
3. Fitusiran: Genzyme, a Sanofi Company/ Alnylam Pharmaceuticals
4. Concizumab (NN7415): Novo Nordisk
5. Marstacimab (PF-06741086): Pfizer
6. AMT-060: UniQure Biopharma B.V.
7. SerpinPC: ApcinteX Ltd
8. FLT180a: Freeline Therapeutics
9. SB-FIX: Sangamo Therapeutics
Request Sample Report- https://www.delveinsight.com/sample-request/hemophilia-b-market
Table of Content
1. Key Insights
2. Hemophilia B Executive Summary
3. Hemophilia B Competitive Intelligence Analysis
4. Hemophilia B: Market Overview at a Glance
5. Hemophilia B: Disease Background and Overview
6. Patient Journey
7. Hemophilia B Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia B Unmet Needs
10. Key Endpoints of Hemophilia B Treatment
11. Hemophilia B Marketed Products
12. Hemophilia B Emerging Therapies
13. Hemophilia B: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Hemophilia B Market Drivers
19. Hemophilia B Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Hemophilia B Market Report Highlights
Why should you buy this report?
Do you have any query or doubt related to the report? If yes, visit here- https://www.delveinsight.com/sample-request/hemophilia-b-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/